Havens Advisors adds Vitae Pharmaceuticals Inc (VTAE) to its portfolio

Vitae Pharmaceuticals Inc (VTAE) : Havens Advisors added new position in Vitae Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 103,760 shares of Vitae Pharmaceuticals Inc which is valued at $2,175,847 , the company said in a statement filed on Oct 13, 2016 with the SEC.Vitae Pharmaceuticals Inc makes up approximately 1.74% of Havens Advisors’s portfolio.

Other Hedge Funds, Including , Creative Planning added VTAE to its portfolio by purchasing 563 company shares during the most recent quarter which is valued at $11,789. Cutler Group Lp added VTAE to its portfolio by purchasing 1,100 company shares during the most recent quarter which is valued at $23,067. Franklin Street Advisors Inc Nc sold out all of its stake in VTAE during the most recent quarter. The investment firm sold 100,800 shares of VTAE which is valued $2,114,784.Bnp Paribas Arbitrage Sa boosted its stake in VTAE in the latest quarter, The investment management firm added 853 additional shares and now holds a total of 1,878 shares of Vitae Pharmaceuticals Inc which is valued at $39,400.

Vitae Pharmaceuticals Inc closed down -0.03 points or -0.14% at $20.94 with 7,05,645 shares getting traded on Tuesday. Post opening the session at $20.97, the shares hit an intraday low of $20.935 and an intraday high of $20.98 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Vitae Pharmaceuticals Inc reported $-0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.41.Analysts expectations of $ .01.The company’s revenue was down -98.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.45 EPS.

Many Wall Street Analysts have commented on Vitae Pharmaceuticals Inc. Vitae Pharmaceuticals Inc was Downgraded by Piper Jaffray to ” Neutral” on Sep 20, 2016. Vitae Pharmaceuticals Inc was Downgraded by Wells Fargo to ” Market Perform” on Sep 15, 2016. Vitae Pharmaceuticals Inc was Downgraded by JMP Securities to ” Mkt Perform” on Aug 4, 2016.

Vitae Pharmaceuticals Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Company’s two partnered product candidates are VTP-34072 which is in a Phase II clinical trial for the treatment of type 2 diabetes and BI 1147560 for the treatment and prevention of Alzheimer’s disease. The Company’s several wholly owned product candidates advancing in preclinical development including VTP-43742 for the treatment of autoimmune disorders VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Vitae Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Vitae Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.